Phase II Data Showing Clinical Benefits of Novel Once-Daily Oral ...
Yahoo! News (press release) - USA
... launched global Phase III pivotal study program called FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis) will include ...

Tysabri

Tysabri's use for MS limited for now
Newsday - Long Island,NY,USA
The Food and Drug Administration recently reapproved Tysabri, a drug that earlier was said to be a big advance in the treatment of multiple sclerosis but ...

New Drug Reduces MS Symptoms
Forbes - USA
... for this disease. The most recently approved drug for MS treatment, available by infusion, is Tysabri (natalizumab). The drug was ...

PDL Biopharma: Troubled Summer, But Holding On
Seeking Alpha - New York,NY,USA
... licensee, Lucentis, and they continue to receive royalties from eight other drugs, including potential (or realized) blockbusters Avastin, Tysabri and Herceptin ...

Drug for MS Reduces Lesions and Extends Time to Relapse
MedPage Today - Little Falls,NJ,USA
... of T-cell migration in patients with multiple sclerosis has been impressively demonstrated by the therapeutic effects of natalizumab [Tysabri], a monoclonal ...

fingolimod

AUDIO SUMMARY
New England Journal of Medicine (subscription) - MA,USA
... uncoated stents in primary percutaneous coronary intervention, chemotherapy with preoperative radiotherapy in rectal cancer, oral fingolimod for relapsing ...

(PRN) - AFC Enterprises to Present at CL King's Best Ideas ...
Bolsamania.com - Madrid,Madrid,Spain
... [+]. (PRN) - Phase II Data Showing Clinical Benefits of Novel Once-Daily Oral Multiple Sclerosis Therapy FTY720 (Fingolimod) Published in New England Journal of ...

FTY720

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
New England Journal of Medicine (subscription) - MA,USA
... MD, Paul O'Connor, MD, Chris H. Polman, MD, Tomas Haas, Ph.D., Alexander A. Korn, Ph.D., Goeril Karlsson, Ph.D., Ernst W. Radue, MD, for the FTY720 D2201 Study ...

(PRN) - Travelport to Webcast Second Quarter 2006 Earnings ...
Bolsamania.com - Madrid,Madrid,Spain
... [+]. (PRN) - Phase II Data Showing Clinical Benefits of Novel Once-Daily Oral Multiple Sclerosis Therapy FTY720 (Fingolimod) Published in New England Journal of ...

Early Results Promising for MS Drug
WebMD - USA
... Fingolimod, also known as FTY720, essentially traps T cells in the lymph nodes, keeping them out of the blood and away from the central nervous system where ...

Novartis Study To Compare New MS Pill To Biogen's Avonex
Easy Bourse (Communiqués de presse) - Paris,France
... They will be divided into equal numbers and will be randomly assigned to receive either the Novartis pill, dubbed FTY720, at a dose of 1.25 milligrams or 0.5 ...